"We are very pleased to appoint Kevin Stark as our CEO," said Jay Lichter, Ph.D., Chairman of the Board. "We believe his experience, which spans basic research to executive management, will be instrumental as the company advances into drug development and seeks potential partnerships."
Dr. Stark received a Ph.D. in Pharmacology from the University of Washington, and a B.S. in Zoology from Colorado State University.
InCode also announced that William St. John has resigned as President and Chief Executive Officer, and will remain on the Board of Directors.
"We are very grateful to Bill for his vision in recognizing the promise of complement depletion in human disease, and his role in building the company to this point," said Carl-Wilhelm Vogel, MD, Ph.D., Founder and Board Member, from the Cancer Research Center of Hawaii.
In conjunction with this transition, the company will shift operations from the San Francisco, CA location to the Thousand Oaks, CA area.
About InCode
InCode's novel approach is focused on the selective interruption of the complement cascade. Activation of the complement cascade has been implicated in the pathogenesis of many inflammatory diseases, including rheumatoid arthritis, asthma, ischemia-reperfusion injury and age-related macular degeneration. Importantly, there is increased appreciation for the role of complement in certain types of cancer.
For more information, contact: info@incodebp.com http://www.incodebp.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Source: InCode BioPharmaceutics, Inc.
